Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11122MR)

This product GTTS-WQ11122MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets TNFRSF8 gene. The antibody can be applied in Hodgkin's disease (HD), Anaplastic large cell lymphoma (ALCL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001243.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 943
UniProt ID P28908
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ11122MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10599MR IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA LY3300054
GTTS-WQ14159MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA aIL6R88
GTTS-WQ1799MR IVTScrip™ mRNA-Anti-CD19, ADCT-402(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ADCT-402
GTTS-WQ7397MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA GA101
GTTS-WQ9787MR IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JS002
GTTS-WQ13495MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA PRTX-100
GTTS-WQ1096MR IVTScrip™ mRNA-Anti-MAPT, ABBV-8E12(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-8E12
GTTS-WQ10364MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY2062430
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW